DNA — Ginkgo Bioworks Holdings Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.86bn
- $917.53m
- $251.46m
- 41
- 17
- 31
- 20
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -120 | -127 | -1,837 | -2,106 | -893 |
Depreciation | |||||
Deferred Taxes | |||||
Non-Cash Items | 53.9 | 3.54 | 1,615 | 1,863 | 498 |
Unusual Items | |||||
Purchased R&D | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 10.6 | -26.5 | -61.5 | -37 | 29.8 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -44.7 | -136 | -254 | -252 | -296 |
Capital Expenditures | -22.2 | -57.8 | -56.5 | -52.3 | -40.8 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -52.4 | -9.3 | -16.7 | -15.1 | -39.9 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -74.6 | -67.1 | -73.3 | -67.4 | -80.7 |
Financing Cash Flow Items | — | — | 50.5 | -2.97 | -2.01 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 410 | 90.3 | 1,534 | 95.3 | -3.22 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 291 | -113 | 1,207 | -223 | -380 |